Transarterial Chemoembolization (TACE) Market : An Overview Report

Introduction:

Transarterial Chemoembolization (TACE) is a minimally invasive procedure used to treat liver cancer. It combines chemotherapy and embolization to target tumors directly. During the procedure, chemotherapy drugs are injected into the blood vessels supplying the tumor, followed by the use of embolic agents to block blood flow, trapping the chemotherapy in the tumor. This treatment is primarily used for patients with hepatocellular carcinoma (HCC) and metastatic liver cancer. TACE has become a preferred treatment option due to its effectiveness in shrinking tumors and prolonging survival rates, making it a key area of growth in the oncology market.

Market Size:

Global transarterial chemoembolization (TACE) market size was valued at USD 2.29 billion in 2023 and is projected to reach USD 4.32 billion by 2031, with a CAGR of 8.25% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

https://www.databridgemarketresearch.com/reports/global-transarterial-chemoembolization-tace-market

Some of the major players operating in the market are:

Questex (U.S.)
Siemens Healthcare GmbH (Germany)
Intermountain Healthcare (U.S.)
Provincial Health Services Authority (Canada)
Cancer Research Institute (U.S.)
Bellicum Pharmaceuticals Inc. (U.S.)
Boston Scientific Corporation (U.S.)
Hikma Pharmaceuticals PLC (Jordan)
Isofol Medical AB (publ) (Sweden)
Nippon Kayaku Co. Ltd. (Japan)
Novartis AG (Switzerland)
Pfizer Inc. (U.S.)
Sirtex SIR-Spheres Pty Ltd. (Australia)
Spectrum Pharmaceuticals, Inc. (U.S.)
F. Hoffmann-La Roche Ltd (Switzerland)
Bayer AG (Germany)
Hepion Pharmaceuticals (U.S.)
Polaris Pharmaceuticals (U.S.)
Chugai Pharmaceutical Co., Ltd. (Japan)
Merck & Co., Inc. (U.S.)

Market Share:

The TACE market is dominated by leading healthcare and pharmaceutical companies specializing in oncology treatment. Key players include Boston Scientific Corporation, Merit Medical Systems, Sirtex Medical, BTG International, and Terumo Corporation. Boston Scientific holds a significant market share with its innovative embolic agents and delivery systems. Sirtex Medical is a major player known for its TACE products used in targeted liver cancer therapy. Merit Medical Systems offers a range of embolotherapy devices widely used in TACE procedures. The market is highly competitive, with companies focusing on product innovation, strategic partnerships, and clinical trials to strengthen their position.

Market Trends:

The TACE market is evolving with several key trends shaping its future. The increasing use of drug-eluting beads (DEB-TACE) is enhancing treatment efficacy. DEB-TACE allows for controlled and sustained drug release, improving patient outcomes and reducing side effects. The growing integration of imaging technologies, such as cone-beam computed tomography (CBCT), during TACE procedures is improving accuracy and treatment precision. The rising adoption of combination therapies, including TACE with immunotherapy or targeted therapy, is gaining attention for its potential to enhance clinical benefits. The development of novel embolic agents with improved biocompatibility and drug-loading capacity is also driving market innovation.

Market Growth:

The TACE market is experiencing significant growth due to the increasing prevalence of liver cancer worldwide. The rising number of liver cancer cases, driven by factors such as hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver disease, is fueling demand for TACE procedures. The expanding use of TACE as a bridging therapy before liver transplantation is contributing to market growth. Advancements in interventional radiology and embolization techniques are improving treatment outcomes and boosting market expansion. The growing awareness of TACE as a palliative treatment for unresectable liver cancer is further driving market growth.

Market Demand:

The demand for TACE procedures is rising as healthcare providers seek effective and minimally invasive cancer treatments. The increasing preference for localized treatment options with fewer systemic side effects is driving demand. The growing use of TACE in combination with systemic therapies is improving patient survival rates, increasing its adoption in clinical settings. The rising number of clinical trials evaluating new embolic agents and combination therapies is creating new opportunities in the market. The expanding healthcare infrastructure and access to interventional oncology services in developing regions are also boosting demand for TACE procedures.

Factors Driving Growth:

Several factors are driving the growth of the TACE market. The rising global burden of liver cancer is the primary growth driver. Technological advancements in embolic agents and drug delivery systems are enhancing treatment efficacy and safety. The increasing availability of interventional oncology services is expanding access to TACE procedures. Government initiatives and funding for cancer research and treatment are supporting market expansion. The growing focus on personalized and targeted cancer therapies is boosting demand for TACE. The increasing preference for minimally invasive procedures with shorter recovery times is contributing to market growth.

Conclusion:

The Transarterial Chemoembolization (TACE) market is expanding rapidly due to the rising prevalence of liver cancer and advancements in interventional oncology. Major industry players are investing in innovative embolic agents, drug delivery systems, and combination therapies to enhance treatment efficacy. The increasing adoption of TACE as a standard treatment for unresectable liver cancer is driving market growth. With continuous technological advancements, growing clinical research activities, and expanding healthcare access, the TACE market is expected to experience significant growth in the coming years.

Browse Reports :

https://kaizokuoninaru.blogspot.com/2025/03/polymer-processing-aid-market-size.html

https://kaizokuoninaru.blogspot.com/2025/03/hyper-converged-infrastructure-market.html

https://solidblogs3.blogspot.com/2025/03/underground-utility-mapping-market-size.html

https://solidblogs3.blogspot.com/2025/03/two-terminal-solar-cell-market-size.html

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.